65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

BACKGROUND: The aim of the study was to investigate in terms of noninferiority the efficacy and safety of a monochemotherapy regimen of pemetrexed plus bevacizumab (BevPem) versus carboplatin/pemetrexed plus bevacizumab (BevCPem) in elderly patients as first-line treatment for advanced metastatic or...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuette, Wolfgang, Schneider, Claus-Peter, Engel-Riedel, Walburga, Schumann, Christian, Kohlhaeufl, Martin, Serke, Monika Heidi Ursel, Hoeffken, Gert, Kortsik, Cornelius, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683796/
https://www.ncbi.nlm.nih.gov/pubmed/29158696
http://dx.doi.org/10.2147/LCTT.S142972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683796/
https://www.ncbi.nlm.nih.gov/pubmed/29158696
http://dx.doi.org/10.2147/LCTT.S142972

Ejemplares similares